PHILLIP GOLDSBOROUGH: Open Payments
NPI 1750081550 · PRINCESS ANNE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$696 in 34 payments from 10 companies in 2025. Trend: 2023 $148 · 2024 $486 · 2025 $696
Food & beverage: $696
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $207 |
| Otsuka America Pharmaceutical, Inc. | 9 | $166 |
| E.R. Squibb & Sons, L.L.C. | 4 | $75 |
| ABBVIE INC. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $38 |
| Janssen Pharmaceuticals, Inc | 1 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
Products named: INGREZZA, COBENFY, ABILIFY MAINTENA, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, UZEDY, SPRAVATO.
Industry payments across MD — which companies pay providers there.
